is honored to present coverage from the 4th Friends of Israel Urological Symposium (FOIU) held in Tel Aviv, Israel. The 2018 Symposium creates an unparalleled opportunity for local and international ...

Endoscopic enucleation of the prostate (EEP) has become a gold standard for the surgical treatment of symptomatic benign prostatic hyperplasia (BPH). Thulium fiber laser enucleation (ThuFLEP), due to ...

Advanced or metastatic urothelial carcinoma (UC) is an incurable disease with a high disease burden and a poor prognosis. Avelumab as first-line (1L) maintenance treatment is an innovative therapy ...

Renal cell carcinoma (RCC) presents a significant diagnostic challenge, particularly in small renal masses. The search for non-invasive screening methods and biomarkers has directed research toward ...

Oxidative stress contributes to benign prostatic hyperplasia (BPH) pathogenesis, but its role in BPH with bladder diverticulum is unclear. This prospective cohort study compared 126 BPH patients at ...

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a bladder disorder with no definite aetiology and currently no effective treatment. Its clinical symptoms vary widely, and the bladder condition ...

Benign prostatic hyperplasia (BPH) is a common condition that affects elderly men, but its relationship with central obesity in the American population has not been adequately elucidated. In this ...

Tranexamic acid (TXA) is an anti-fibrinolytic agent that prevents degradation of fibrin by blocking the ability of plasminogen to bind to fibrin and the proteolytic activity of plasmin. TXA has been ...

There is a high number of acute renal colic cases that present to the emergency department, and it is crucial to have reliable parameters that can accurately predict the likelihood of spontaneous ...